Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum –
– Late-stage product candidate, SB204 for the treatment of acne vulgaris, selected to advance as second lead program toward pivotal Phase 3 study –
– SB019 SARS-CoV-2 development program advancing toward Phase 1 study in healthy volunteers, targeted for 1H 2022 –
– Company to host conference call and webcast today at 8:30 AM ET –
Upcoming Targeted Milestones:
Initiation of Phase 1 study in healthy volunteers targeted for 2022.
Phase 2/3 study(s) targeted for 2023, subject to obtaining additional financing or strategic partnering.
Potential submission of an NDA targeted for 2024.
Conference Call and Webcast Details
As previously announced, Novan will host a corporate update conference call and webcast today, Thursday, September 9th at 8:30 a.m. ET. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (844) 707-0661 (domestic) or (703) 318-2240 (international) and referencing conference ID: 6243828. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.
https://finance.yahoo.com/news/novan-announces-strategic-priorities-outlines-110000040.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.